Related Experiment Video
Updated: May 10, 2025
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.3K
Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol
Gerardo Gutiérrez-Gutiérrez1, Rocío Gómez-Ballesteros2, Javier Sotoca3
1Department of Neurology, Hospital Universitario Infanta Sofía, Madrid, Spain.
Plos One
|April 22, 2025
Summary
Neurologists face complex choices for generalized myasthenia gravis (gMG) treatments due to new options. This study explores their preferences and the factors influencing these critical therapeutic decisions.
Area of Science:
- Neurology
- Clinical Decision-Making
- Pharmacoeconomics
Background:
- The generalized myasthenia gravis (gMG) treatment landscape has rapidly evolved with multiple new targeted therapies.
- Physicians grapple with selecting optimal treatments balancing efficacy, safety, and patient preferences.
- Understanding neurologist decision-making is crucial amidst evolving therapeutic options.
Purpose of the Study:
- To investigate neurologists' preferred treatment choices for gMG.
- To identify demographic, professional, and behavioral factors influencing gMG treatment decisions.
- To analyze therapeutic inertia in gMG management.
Main Methods:
- A non-interventional, cross-sectional, web-based study involving 150 neurologists treating gMG patients.
- Conjoint analysis to assess preferences for gMG treatment attributes using hypothetical scenarios.
- Evaluation of therapeutic inertia via clinical case scenarios and a survey on neurologist characteristics.
Main Results:
- (Results not yet available in the abstract)
Conclusions:
- Study findings will enhance understanding of gMG treatment decision-making.
- Identifies key factors influencing neurologists' choices in a dynamic therapeutic environment.
- Provides insights for optimizing gMG patient care strategies.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
538
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
538
01:20Myasthenia Gravis: Overview and Treatment
958
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
958
01:28Disorders of the Skeletal Muscle
826
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
826
01:21Skeletal Muscle Relaxants: Adverse Effects
309
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
309
01:31Skeletal Muscle Relaxants: Therapeutic Uses
439
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
439